US$ 21.40
retatrutide glp1 a Triple Agonist (GLP-1/GIP/GCG) Unapproved weight loss drug retatrutide
Description
The study found that this class of medications significantly increases the risk of developing gastroparesis and other gastrointestinal disorders
In-house analytics, such as form guides and head-to-head histories, add meaningful context without overwhelming the screen

Volume restoration via filler or fat grafting is supported by the strongest evidence

It mimics GLP-1, a natural gut hormone, to regulate blood sugar, increase insulin, suppress appetite, and promote long-term weight loss
Comparison reflects publicly listed features and pricing for Ro Body, Mochi Health, TrimRx, and Hims as of April 2026

P = 0.05
